nach oben

Cardiovascular Toxicology

Erschienen in:

08.05.2018

Serum miR-30c Level Predicted Cardiotoxicity in Non-small Cell Lung Cancer Patients Treated with Bevacizumab

verfasst von: Fang Zhou, Xike Lu, Xun Zhang

Erschienen in: Cardiovascular Toxicology | Ausgabe 3/2018

Einloggen, um Zugang zu erhalten

Abstract

Cardiotoxicity is a common adverse effect induced by drug chemotherapy. miR-30c has been reported to be involved in the progress of heart diseases. In the present study, miR-30c was used to predict the cardiotoxicity in non-small cell lung cancer (NSCLC) patients treated with bevacizumab chemotherapy. Eighty NSCLC patients were included in this study. Serum miR-30c levels were detected at pre-chemotherapy, during-chemotherapy (the 2nd, 4th, and 8th week) and 1 month after chemotherapy. miR-30c expression was elevated with the duration of the chemotherapy cycle and decreased 1 month after chemotherapy. The correlation analysis showed that serum miR-30c levels were positively related to cardiotoxicity before chemotherapy and during chemotherapy. ROC curve analysis showed the values of AUC, sensitivity, and specificity for the level of miR-30c alteration (from pre-chemotherapy to during-chemotherapy) were 0.851, 0.720, and 0.860, respectively. Serum miR-30c level is elevated during bevacizumab chemotherapy, which is probably an early detection biomarker for predicting cardiotoxicity in NSCLC patients treated with drug chemotherapy.

Nur mit Berechtigung zugänglich

Siegel, R., et al. (2014). Cancer statistics, 2014. CA: A Cancer Journal for Clinicians, 64(1), 9–29.

Iyer, S., et al. (2014). The symptom burden of non-small cell lung cancer in the USA: A real-world cross-sectional study. Supportive Care in Cancer, 22(1), 181–187.CrossRefPubMed

Gridelli, C., et al. (2007). The role of bevacizumab in the treatment of non-small cell lung cancer: Current indications and future developments. The Oncologist, 12(10), 1183–1193.CrossRefPubMed

Lauro, S., et al. (2014). The use of bevacizumab in non-small cell lung cancer: An update. Anticancer Research, 34(4), 1537–1545.PubMed

Ding, L., et al. (2014). The efficacy and safety of pemetrexed plus bevacizumab in previously treated patients with advanced non-squamous non-small cell lung cancer (ns-NSCLC). Tumor Biology, 36(4), 2491–2499.

Kruzliak, P., Novak, J., & Novak, M. (2014). Vascular endothelial growth factor inhibitor-induced hypertension: From pathophysiology to prevention and treatment based on long-acting nitric oxide donors. American Journal of Hypertension, 27(1), 3–13.CrossRefPubMed

Choueiri, T. K., et al. (2011). Congestive heart failure risk in patients with breast cancer treated with bevacizumab. Journal of Clinical Oncology, 29(6), 632–638.CrossRefPubMed

Yeung, S. L., Lam, H. S., & Schooling, C. M. (2017). Vascular endothelial growth factor and ischemic heart disease risk: A mendelian randomization study. Journal of the American Heart Association, 6(8), e005619.CrossRef

Hueso, L., et al. (2017). Dynamics and implications of circulating anti-angiogenic VEGF-A165b isoform in patients with ST-elevation myocardial infarction. Scientific Reports, 7(1), 9962.CrossRefPubMedPubMedCentral

10.

Wang, X., et al. (2017). Intratracheal administration of isosorbide dinitrate improves pulmonary artery pressure and ventricular remodeling in a rat model of heart failure following myocardial infarction. Experimental and Therapeutic Medicine, 14(2), 1399–1408.CrossRefPubMedPubMedCentral

11.

Sandhu, H., & Maddock, H. (2014). Molecular basis of cancer-therapy-induced cardiotoxicity: Introducing microRNA biomarkers for early assessment of subclinical myocardial injury. Clinical Science, 126(6), 377–400.CrossRefPubMed

12.

Bartel, D. P. (2004). MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell, 116(2), 281–297.CrossRefPubMed

13.

Lawrence, P., & Ceccoli, J. (2017). Advances in the application and impact of MicroRNAs as therapies for skin disease. BioDrugs, 31(5), 423–438.CrossRef

14.

Pallez, D., Gardes, J., & Pasquier, C. (2017). Prediction of miRNA-disease associations using an evolutionary tuned latent semantic analysis. Scientific Reports, 7(1), 10548.CrossRefPubMedPubMedCentral

15.

Hirt, M. N., et al. (2015). Deciphering the microRNA signature of pathological cardiac hypertrophy by engineered heart tissue- and sequencing-technology. Journal of Molecular and Cellular Cardiology, 81, 1–9.CrossRefPubMed

16.

Hou, Y., et al. (2012). Beta-adrenoceptor regulates miRNA expression in rat heart. Medical Science Monitor, 18(8), BR309–BR314.

17.

Bao, J. L., & Lin, L. (2014). MiR-155 and miR-148a reduce cardiac injury by inhibiting NF-kappaB pathway during acute viral myocarditis. European Review for Medical and Pharmacological Sciences, 18(16), 2349–2356.PubMed

18.

Lagos-Quintana, M., et al. (2002). Identification of tissue-specific microRNAs from mouse. Current Biology, 12(9), 735–739.CrossRefPubMed

19.

Abonnenc, M., et al. (2013). Extracellular matrix secretion by cardiac fibroblasts: Role of microRNA-29b and microRNA-30c. Circulation Research, 113(10), 1138–1147.CrossRefPubMed

20.

Yanaihara, N., et al. (2006). Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell, 9(3), 189–198.CrossRefPubMed

21.

Panizo, S., et al. (2017) Regulation of miR-29b and miR-30c by vitamin D receptor activators contributes to attenuate uraemia-induced cardiac fibrosis. Nephrology Dialysis Transplantation, 32(11), 1831–1840CrossRef

22.

Martín, M., et al. (2009). Minimizing cardiotoxicity while optimizing treatment efficacy with trastuzumab: Review and expert recommendations. The Oncologist, 14(1), 1–11.CrossRefPubMed

23.

Cakmak, H., et al. (2017). Effects of sunitinib and bevacizumab on VEGF and miRNA levels on corneal neovascularization. Cutaneous and Ocular Toxicology, 37(2), 191–195.

24.

Ferrara, N., Hillan, K. J. & Novotny, W. (2005). Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochemical and Biophysical Research Communications, 333(2), 328–335.CrossRefPubMed

25.

Giordano, F. J., et al. (2001). A cardiac myocyte vascular endothelial growth factor paracrine pathway is required to maintain cardiac function. Proceedings of the National Academy of Sciences of the United States of America, 98(10), 5780–5785.

26.

Hong, I. H., & Park, S. P. (2017). Quantitative physiological measurements to evaluate the response of antivascular endothelial growth factor treatment in patients with neovascular diseases. Indian Journal of Ophthalmology, 65(7), 559–568.CrossRefPubMedPubMedCentral

27.

Deuse, T., et al. (2009). Hepatocyte growth factor or vascular endothelial growth factor gene transfer maximizes mesenchymal stem cell-based myocardial salvage after acute myocardial infarction. Circulation, 120(11 Suppl), S247–S254.

28.

Liu, X., et al. (2016). miR-30c regulates proliferation, apoptosis and differentiation via the Shh signaling pathway in P19 cells. Experimental & Molecular Medicine, 48(7), e248.CrossRef

29.

Gu, Y., et al. (2013). miR-30b and miR-30c expression predicted response to tyrosine kinase inhibitors as first line treatment in non-small cell lung cancer. Chinese Medical Journal, 126(23), 4435–4439.PubMed

30.

Jentzsch, C., et al. (2012). A phenotypic screen to identify hypertrophy-modulating microRNAs in primary cardiomyocytes. Journal of Molecular and Cellular Cardiology, 52(1), 13–20.CrossRefPubMed

31.

Irani, S., & Hussain, M. M. (2015). Role of microRNA-30c in lipid metabolism, adipogenesis, cardiac remodeling and cancer. Current Opinion in Lipidology, 26(2), 139–146.CrossRefPubMed

32.

Sayed, D., et al. (2007). MicroRNAs play an essential role in the development of cardiac hypertrophy. Circulation Research, 100(3), 416–424.CrossRefPubMed

33.

Duisters, R.F., et al. (2009). miR-133 and miR-30 regulate connective tissue growth factor: Implications for a role of microRNAs in myocardial matrix remodeling. Circulation Research, 104(2), 170–178.CrossRefPubMed

34.

Chino, H., et al. (2016). Cardiogenic syncope possibly related to bevacizumab-containing combination chemotherapy for advanced non-small cell lung cancer. Journal of Thoracic Disease, 8(9), 2646–2650.CrossRefPubMedPubMedCentral

Titel: Serum miR-30c Level Predicted Cardiotoxicity in Non-small Cell Lung Cancer Patients Treated with Bevacizumab
verfasst von: Fang Zhou
Xike Lu
Xun Zhang
Publikationsdatum: 08.05.2018
Verlag: Springer US
Erschienen in: Cardiovascular Toxicology / Ausgabe 3/2018
Print ISSN: 1530-7905
Elektronische ISSN: 1559-0259
DOI: https://doi.org/10.1007/s12012-018-9457-z

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2018

Beneficial Role of Some Natural Products to Attenuate the Diabetic Cardiomyopathy Through Nrf2 Pathway in Cell Culture and Animal Models

Novel Mesenchymal Stem Cell Strategy in Alleviating Toll-Like Receptor-4, p53 and Nrf2 Signaling in Isoproterenol-Induced Myocardial Infarction in Rat Model

A Fatal Case of Amlodipine Toxicity Following Iatrogenic Hypercalcemia

Characteristics of Cobalt-Related Cardiomyopathy in Metal Hip Implant Patients: An Evaluation of 15 Published Reports

The Role of Soluble Epoxide Hydrolase Enzyme on Daunorubicin-Mediated Cardiotoxicity

Alleviation of Cardiac Damage by Dietary Fenugreek (Trigonella foenum-graecum) Seeds is Potentiated by Onion (Allium cepa) in Experimental Diabetic Rats via Blocking Renin–Angiotensin System